Atlas of Psychiatric PharmacotherapyThe second edition of this exceptional book provides a comprehensive understanding of the mechanisms of action involved in psychiatric pharmacotherapy. Using imaginative colourful double-page spreads, this exceptional book presents state-of-the-art information on all the basic principles of psychiatric pharmacotherapy, abused substances, drug inter |
Contents
Chapter 2 Antidepressant drugs and mood stabilizers | 25 |
Chapter 3 Anxiolytic drugs | 67 |
Chapter 4 Antipsychotic drugs | 89 |
Chapter 5 Drugs affecting sexual function | 105 |
Chapter 6 Drugs for the treatment of symptoms related to substance abuse | 115 |
Chapter 7 Miscellaneous drugstreatment modalities | 147 |
Other editions - View all
Atlas of Psychiatric Pharmacotherapy, Second Edition Roni Shiloh,Rafael Stryjer,Abraham Weizman,David J. Nutt No preview available - 2006 |
Common terms and phrases
abuse acid action activity acute addition administration adverse agents alcohol alter antagonists antidepressant Antipsychotic drugs APDs associated beneficial benzodiazepines bipolar brain bupropion buspirone capacity carbamazepine cause central chronic citalopram Clin clinical clomipramine clozapine combined concentration consequent considered controlled currently decrease depression disorder dopamine dopaminergic dose effects efficacy enhance enzymes especially established et al evidence factor fluoxetine fluvoxamine function GABA haloperidol improvement increase induce inhibition interactions leading Legend lithium major depressive mania MAOIs mechanism medication metabolism mirtazapine moclobemide Monoamine oxidase mood Name of modality neurons neurotransmitter norepinephrine Notes olanzapine paroxetine pathway patients pharmacokinetic plasma postsynaptic potential presynaptic Psychiatry receptor subtype reduce relatively reported response risk scheme schizophrenia Selective serotonin reuptake serotonergic serotonin reuptake inhibitors sertraline serum levels serum levels/effects severe SGAs shown side-effects significant specific SSRIs Stimulates studies suggest symptoms TCAs therapeutic therapy topiramate toxicity transmission transporter treatment trials Tricyclic valproate various venlafaxine